NDAORALTABLET
Approved
Apr 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROMOX (quinethazone) is an oral thiazide diuretic tablet approved in 1963 for hypertension and edema management. It reduces fluid retention and blood pressure through renal sodium excretion. This is a legacy small-molecule antihypertensive with established clinical utility in patients requiring diuretic therapy.
LOE Approaching
As a legacy diuretic approaching loss of exclusivity with moderate competitive pressure (30%), commercial teams are likely focused on cost optimization and niche market retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYDROMOX offers limited career growth potential given its approach to loss of exclusivity and minimal linked job opportunities. This role is best suited for professionals seeking stability in mature-market management, regulatory expertise, or field-based sales in cost-conscious healthcare segments.
Brand ManagerRegulatory Specialist
Worked on HYDROMOX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.